Home / FDA Rejects BioMarin's Duchenne Treatment

FDA Rejects BioMarin's Duchenne Treatment

The FDA's decision to reject Biomarin's drug for Duchenne muscular dystrophy comes on the heels of an FDA Advisory Committee meeting in November in which experts expressed concern about its efficacy and side effects. An Advisory Committee meeting for "eteplirsen," a similar antisense oligo-based drug for Duchenne developed by Sarepta will take place on January 22nd.

Read more about that meeting here.

Read the Reuters article on the Kendrisa rejection here.

 

Partners

University of Florida Logo 100px.png Houston Methodist Logo 100px.png University of Iowa 100px.png University of Kansas Logo 100px.png National Institute of Health 100px.png Ohio State University Logo 100px.png University of Rochester 100px.png Stanford University Logo 100px.png University of Utah Logo 100px.png Virginia Commonwealth University Logo 100px.png Wyck Logo 150px.png

© Myotonic Dystrophy Foundation. All rights reserved.